LL-37: Clinical Guide for Prescribing Practices
LL-37 is the only human cathelicidin antimicrobial peptide, playing roles in innate immune defense, wound healing, and immune modulation. It has broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, and is being investigated for chronic infections, biofilm disruption, and immune optimization.
Also Known As
How LL-37 Works
LL-37 is a 37-amino acid amphipathic alpha-helical peptide that disrupts microbial membranes through electrostatic interaction with negatively charged phospholipids, forming toroidal pores that lead to rapid membrane depolarization and cell lysis [2]. Beyond direct antimicrobial activity, LL-37 binds formyl peptide receptor-like 1 (FPRL1) on immune cells, promoting chemotaxis of neutrophils, monocytes, and T-cells to infection sites [3]. It also neutralizes lipopolysaccharide (LPS), preventing TLR4 activation and reducing sepsis-associated inflammatory cascades [4].
Clinical Evidence
In vitro studies demonstrate broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, enveloped viruses, and fungi at micromolar concentrations [2]. A 2008 study in Infection and Immunity confirmed LL-37 disrupts established Pseudomonas aeruginosa biofilms at sub-MIC concentrations [1]. Clinical observations in patients with vitamin D deficiency (which reduces endogenous LL-37 expression) show increased susceptibility to infections, providing indirect evidence for its physiological importance [3]. Direct therapeutic administration data in humans is limited to small case series and clinical practice reports, primarily in integrative medicine settings.
Clinical Uses
Patient Selection and Screening
Most appropriate for patients with chronic infections involving biofilm (chronic sinusitis, Lyme disease adjunct protocols, recurrent urinary tract infections) [1], recurrent infections suggesting innate immune deficiency, and post-viral immune recovery. Patients with documented low vitamin D levels (which correlate with reduced endogenous LL-37 production) may particularly benefit [3]. Caution in patients with psoriasis or rosacea, as elevated LL-37 is implicated in the pathogenesis of these conditions [2]. Avoid in patients with active autoimmune conditions involving excessive neutrophilic inflammation.
Dosing and Administration
Subcutaneous injection: 50 to 100 mcg daily or every other day for 4 to 8 week courses. Intranasal formulations: 50 to 100 mcg per nostril twice daily for upper respiratory and sinus applications [1]. Some protocols use a loading phase of daily injections for 2 weeks followed by every-other-day maintenance. Treatment duration depends on clinical indication; chronic biofilm-associated infections may require longer courses (8 to 12 weeks). Reassess with appropriate infection markers and clinical response at 4-week intervals.
Route: Subcutaneous injection, intranasal
Protocol notes: Administered via subcutaneous injection. Dosing protocols are emerging and vary by clinical indication. Some providers use intranasal formulations for upper respiratory applications.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
LL-37 occupies a specialized niche in practices treating complex chronic infections, particularly Lyme disease protocols and chronic sinusitis [1]. While patient volume is smaller than mainstream peptides, treatment courses are often extended (8 to 12 weeks) and combined with complementary antimicrobial strategies, generating consistent revenue per patient. Practices with established chronic infection or integrative immunology programs can position LL-37 as a foundational component of multi-modal anti-infective protocols [2].
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe LL-37 through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What conditions are most commonly treated with LL-37?
How does LL-37 work against biofilms?
References
- Overhage J, et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76(9):4176-4182.
- Vandamme D, et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22-35.
- Wang G. Human antimicrobial peptides and proteins. Pharmaceuticals (Basel). 2014;7(5):545-594.
- Bucki R, et al. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch Immunol Ther Exp. 2010;58(1):15-25.
Related Peptides in Immune Support
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe LL-37 Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe LL-37 Through Karpa